GERD and H. pylori on the NP Exam: PPI Trials, Alarm Features, Testing and Eradication Regimens

Typical GERD is a clinical diagnosis that the provider treats empirically: heartburn and regurgitation with no alarm features earn an 8-week trial of a once-daily proton pump inhibitor (PPI) taken 30 to 60 minutes before a meal. If symptoms resolve, the next job is to step the PPI down; if they do not, the next step is endoscopy off PPI, not an indefinite escalation. H. pylori is a separate decision with its own rules: test only when there is an indication, treat a positive result first with 14 days of bismuth quadruple therapy under the 2024 ACG guideline, and prove eradication with a non-serologic test at least 4 weeks after treatment.

The exam rewards candidates who keep these two pathways distinct and who know exactly where each one forks.

Assessment: is this typical GERD?

The ACG 2022 GERD guideline treats heartburn (retrosternal burning) and regurgitation as the typical symptoms. When both are present and nothing else in the history is concerning, the pretest probability of GERD is high enough to treat without testing.

Three presentations need a different approach:

• Chest pain. Cardiac causes are excluded first. Only then is reflux considered as a source of noncardiac chest pain.
• Extraesophageal symptoms alone. Chronic cough, hoarseness, throat clearing, globus or asthma without heartburn or regurgitation should not be called GERD on symptoms. The guideline recommends looking for non-GERD causes and doing reflux testing before starting PPI therapy in this group. Patients with both typical and extraesophageal symptoms can have a PPI trial.
• Dyspepsia rather than heartburn. Epigastric pain or fullness is evaluated under the ACG and CAG dyspepsia guideline: endoscopy for patients aged 60 or older, and for younger patients a test-and-treat approach to H. pylori before empiric acid suppression.

Alarm features

Alarm features move a patient off the empiric pathway and onto endoscopy.

Diagnostic pathway: when empiric treatment is enough

Endoscopy is done off PPI so that healing does not hide erosive esophagitis. Severe erosive esophagitis (Los Angeles grade C or D), Barrett's esophagus or a peptic stricture confirms GERD and changes the long-term plan.

Barrett's esophagus screening

The 2022 ACG Barrett's guideline suggests a single screening endoscopy for patients with chronic GERD symptoms and 3 or more additional risk factors: male sex, age over 50, White race, tobacco smoking, obesity, and a family history of Barrett's esophagus or esophageal adenocarcinoma. A common distractor uses the older threshold of 2 risk factors or offers screening to every patient with heartburn.

First-line management of GERD

Lifestyle measures

The ACG 2022 guideline supports targeted lifestyle changes rather than blanket restriction:

• Weight loss for patients with overweight or obesity.
• Avoiding meals within 2 to 3 hours of bedtime.
• Elevating the head of the bed for nighttime symptoms.
• Stopping tobacco.
• Avoiding the patient's own trigger foods, rather than a fixed elimination list.

The PPI trial

• Start a once-daily PPI, taken 30 to 60 minutes before a meal (most agents work best before breakfast; dexlansoprazole can be taken without regard to meals).
• Common standard doses are omeprazole 20 mg, lansoprazole 30 mg and pantoprazole 40 mg once daily.
• Continue for 8 weeks, then reassess.
• If the response is partial, check timing and adherence first. Increasing to twice daily or switching to a different PPI is reasonable before declaring failure.
• Refractory GERD means persistent symptoms despite an optimized course, usually twice-daily PPI for 8 weeks. That patient needs objective testing, not a third PPI.

Other agents

• H2 receptor antagonists help with breakthrough nighttime symptoms or on-demand use, but tachyphylaxis limits continuous use.
• Antacids and alginates give rapid, short-lived relief.
• Metoclopramide is not recommended for GERD, alone or as an add-on, unless gastroparesis has been documented, because of the risk of tardive dyskinesia.
• Antireflux surgery or endoscopic procedures are for carefully selected patients with objective GERD, usually after specialist evaluation.

Stepping down and long-term therapy

Once symptoms resolve, the default question is whether the patient still needs a daily PPI. For patients without severe erosive esophagitis or Barrett's esophagus, the guideline supports tapering to the lowest effective dose, switching to on-demand PPI or an H2 receptor antagonist, or stopping. Patients with Los Angeles grade C or D esophagitis or Barrett's esophagus stay on maintenance PPI.

When symptoms return each time the PPI is stopped and GERD has never been proven, the provider should arrange endoscopy, and reflux monitoring when endoscopy is normal, before labeling the patient as needing lifelong therapy. Concerns about long-term PPI associations are a reason to confirm the indication and use the lowest effective dose, not a reason to withdraw therapy from a patient who needs it.

H. pylori: who should be tested

Test when a positive result will lead to treatment. Common indications include:

• Active or prior peptic ulcer disease.
• Gastric MALT lymphoma, or history of endoscopic resection of early gastric cancer.
• Uninvestigated dyspepsia in a patient under 60 without alarm features.
• Unexplained iron deficiency anemia, and idiopathic thrombocytopenic purpura in adults.
• Long-term low-dose aspirin or planned chronic NSAID therapy.
• A family history of gastric cancer, and adult household members of a person with H. pylori.

Choosing the test

An H2 receptor antagonist can control symptoms while the PPI is held.

H. pylori treatment regimens

The 2024 ACG guideline changed first-line therapy. Clarithromycin resistance is common enough in North America that empiric clarithromycin triple therapy is no longer acceptable.

Practical points:

• Tetracycline is the drug in the quadruple regimen; doxycycline is not an equivalent substitute in the guideline's optimized regimen.
• Patients with a penicillin allergy label receive bismuth quadruple therapy. Many penicillin allergy labels are not true allergies, and allergy evaluation can open up amoxicillin-based options later.
• Tetracycline is avoided in pregnancy, which pushes the decision toward specialist input.

Test of cure and follow-up

Every patient treated for H. pylori needs a test of cure. Use a urea breath test or stool antigen test at least 4 weeks after completing therapy, with the PPI held for 2 weeks beforehand. Persistent infection should not be retreated with the same regimen. After failed bismuth quadruple therapy, the guideline suggests rifabutin triple therapy; after repeated failures, refer to gastroenterology for susceptibility-guided treatment.

For GERD, reassess at the end of the 8-week trial, again after each step-down, and at any recurrence. Patients on maintenance therapy should be reviewed periodically for the ongoing indication and the lowest effective dose.

Referral triggers

• Any alarm feature: endoscopy, with urgency matched to the finding (active bleeding needs emergency care).
• GERD refractory to an optimized PPI course.
• Barrett's esophagus or severe erosive esophagitis for surveillance and management.
• Extraesophageal symptoms needing reflux testing.
• Candidates for antireflux surgery or endoscopic therapy.
• H. pylori that persists after two treatment courses, or treatment in pregnancy.

Patient education

• Take the PPI 30 to 60 minutes before a meal, every day during the trial. A PPI taken at bedtime on an empty stomach works poorly.
• Expect an attempt to lower or stop the PPI once symptoms settle; rebound heartburn for a few days after stopping is common and does not by itself mean the drug is needed again.
• The bismuth regimen involves many pills taken four times a day. Completing all 14 days matters more than any single dose.
• Bismuth darkens stool and the tongue; this is expected. Black, tarry, sticky stool with weakness or dizziness is different and needs urgent care.
• Return for the test of cure, and stop the PPI 2 weeks before it.
• Household members may need testing.
• Report trouble swallowing, vomiting blood, black stools, weight loss or fatigue promptly.

How the exam tests this

• Empiric PPI despite an alarm feature. A vignette mentions dysphagia or iron deficiency anemia in passing; the correct answer is endoscopy, not a PPI trial.
• Escalation without testing. After failure of twice-daily PPI, options such as adding a prokinetic or switching to a third PPI are distractors. The answer is endoscopy off PPI.
• Old first-line regimen. Clarithromycin triple therapy for 7 to 10 days is the classic wrong answer. Under the 2024 guideline, 14-day bismuth quadruple therapy is the preferred first line.
• Wrong test for cure. Serology is never a test of cure. Breath or stool testing done while the patient is still on a PPI, or 1 week after finishing antibiotics, is also wrong.
• Barrett's screening threshold. Screening requires chronic GERD plus 3 or more risk factors, not GERD alone.
• Extraesophageal symptoms. Chronic cough without heartburn calls for evaluation of other causes and reflux testing, not an automatic PPI label.
• Metoclopramide as add-on therapy. Not recommended without documented gastroparesis.

Practice question

A 46-year-old woman returns to the clinic after a stool antigen test ordered for 3 months of epigastric burning was positive for H. pylori. She has no dysphagia, weight loss, vomiting or melena, and her hemoglobin is normal. She has never been treated for H. pylori and has no drug allergies. She takes no medications. Which of the following is the most appropriate treatment?

• A. Omeprazole, clarithromycin and amoxicillin twice daily for 7 days
• B. Omeprazole twice daily, bismuth, tetracycline and metronidazole for 14 days
• C. Omeprazole, levofloxacin and amoxicillin for 10 days
• D. Omeprazole 20 mg daily for 8 weeks, then retest with serology

Answer: B. The 2024 ACG guideline recommends optimized bismuth quadruple therapy for 14 days as first-line treatment for treatment-naive patients, regardless of allergy status. Option A uses clarithromycin empirically and for too short a course; clarithromycin triple therapy is reserved for documented susceptibility. Option C is a levofloxacin-based regimen that is not a recommended empiric first-line choice and exposes the patient to fluoroquinolone harms. Option D treats symptoms without eradicating the infection and uses serology, which cannot confirm cure because antibodies persist.

Key points

Related NPPace guides

• Irritable Bowel Syndrome in Primary Care: Rome IV Diagnosis, Red Flags and Treatment by Subtype
• Abnormal Liver Enzymes: Patterns, the First Work-Up and When to Refer
• Chronic Kidney Disease for the NP Exam: KDIGO Staging, Albuminuria, Kidney-Protective Drugs and Dose Adjustment
• How to Read a Primary-Care Vignette Like a Provider: The 5-Step Method
• AANP vs ANCC: Which NP Certification Exam Should You Take?